152 related articles for article (PubMed ID: 28708203)
1. Medical treatment of erectile dysfunction: too many medical prescriptions?
Capogrosso P; Ventimiglia E; Oreggia D; Salonia A; Montorsi F
Urologia; 2017 Aug; 84(3):121-129. PubMed ID: 28708203
[TBL] [Abstract][Full Text] [Related]
2. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
Yafi FA; Sharlip ID; Becher EF
Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
[TBL] [Abstract][Full Text] [Related]
3. Multiple PDE5Is use as a marker of decreased overall men's health: A real-life study.
Oreggia D; Ventimiglia E; Capogrosso P; Boeri L; Cazzaniga W; Pederzoli F; Chierigo F; Dehò F; Montorsi F; Salonia A
PLoS One; 2018; 13(8):e0201601. PubMed ID: 30096166
[TBL] [Abstract][Full Text] [Related]
4. The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction.
Ventimiglia E; Capogrosso P; Montorsi F; Salonia A
Expert Opin Drug Saf; 2016; 15(2):141-52. PubMed ID: 26752541
[TBL] [Abstract][Full Text] [Related]
5. An update on the drug safety of treating erectile dysfunction.
Gul M; Serefoglu EC
Expert Opin Drug Saf; 2019 Oct; 18(10):965-975. PubMed ID: 31433252
[No Abstract] [Full Text] [Related]
6. Erectile Dysfunction Medications and Treatment for Cardiometabolic Risk Factors: A Pharmacoepidemiologic Study.
Skeldon SC; Cheng L; Morgan SG; Detsky AS; Goldenberg SL; Law MR
J Sex Med; 2017 Dec; 14(12):1597-1605. PubMed ID: 29198514
[TBL] [Abstract][Full Text] [Related]
7. Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Loeb S; Folkvaljon Y; Lambe M; Robinson D; Garmo H; Ingvar C; Stattin P
JAMA; 2015 Jun 23-30; 313(24):2449-55. PubMed ID: 26103029
[TBL] [Abstract][Full Text] [Related]
8. Characteristics, behaviors, and attitudes of men bypassing the healthcare system when obtaining phosphodiesterase type 5 inhibitors.
Schnetzler G; Banks I; Kirby M; Zou KH; Symonds T
J Sex Med; 2010 Mar; 7(3):1237-46. PubMed ID: 20136707
[TBL] [Abstract][Full Text] [Related]
9. Two Birds with One Stone: Regular Use of PDE5 Inhibitors for Treating Male Patients with Erectile Dysfunction and Cardiovascular Diseases.
Cai Z; Zhang J; Li H
Cardiovasc Drugs Ther; 2019 Feb; 33(1):119-128. PubMed ID: 30675707
[TBL] [Abstract][Full Text] [Related]
10. Effect of Genetic Polymorphism on the Response to PDE5 Inhibitors in Patients With Erectile Dysfunction: A Systematic Review and a Critical Appraisal.
Mostafa T; Hassan A; Alghobary MF; Abdelrahman SH
Sex Med Rev; 2020 Oct; 8(4):573-585. PubMed ID: 32636154
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.
Chen L; Staubli SE; Schneider MP; Kessels AG; Ivic S; Bachmann LM; Kessler TM
Eur Urol; 2015 Oct; 68(4):674-80. PubMed ID: 25817916
[TBL] [Abstract][Full Text] [Related]
12. Avanafil - a further step to tailoring patient needs and expectations.
Boeri L; Capogrosso P; Ventimiglia E; Serino A; La Croce G; Russo A; Damiano R; Montorsi F; Salonia A
Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1171-81. PubMed ID: 27232892
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors.
Hong JH; Kwon YS; Kim IY
Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):183-192. PubMed ID: 27690667
[TBL] [Abstract][Full Text] [Related]
14. Advances in pharmacotherapy for erectile dysfunction and associated cardiac impact.
Voznesensky I; DeLay KJ; Hellstrom WJ
Expert Opin Pharmacother; 2016 Dec; 17(17):2281-2289. PubMed ID: 27677349
[TBL] [Abstract][Full Text] [Related]
15. Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preoperative erectile function.
Basal S; Wambi C; Acikel C; Gupta M; Badani K
BJU Int; 2013 Apr; 111(4):658-65. PubMed ID: 23186312
[TBL] [Abstract][Full Text] [Related]
16. Drug prescription for erectile dysfunction before and after diagnosis of localized prostate cancer.
Plym A; Folkvaljon Y; Garmo H; Holmberg L; Johansson E; Fransson P; Stattin P; Lambe M
J Sex Med; 2014 Aug; 11(8):2100-8. PubMed ID: 24862360
[TBL] [Abstract][Full Text] [Related]
17. Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.
Hsu JC; Tang DH; Lu CY
Int J Clin Pract; 2015 Apr; 69(4):436-43. PubMed ID: 25311239
[TBL] [Abstract][Full Text] [Related]
18. How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors.
Jannini EA; DeRogatis LR; Chung E; Brock GB
J Sex Med; 2012 Jan; 9(1):26-33. PubMed ID: 22221307
[TBL] [Abstract][Full Text] [Related]
19. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the efficacy of combination therapy with folic acid and tadalafil for the management of erectile dysfunction in men with type 2 diabetes mellitus.
Hamidi Madani A; Asadolahzade A; Mokhtari G; Shahrokhi Damavand R; Farzan A; Esmaeili S
J Sex Med; 2013 Apr; 10(4):1146-50. PubMed ID: 23347176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
